A 12-week, Multi-center, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study Examining Seizure Frequency of BGG492 Capsules as Adjunctive Treatment in Patients With Partial Onset Seizures.

Trial Profile

A 12-week, Multi-center, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study Examining Seizure Frequency of BGG492 Capsules as Adjunctive Treatment in Patients With Partial Onset Seizures.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 May 2017

At a glance

  • Drugs Selurampanel (Primary)
  • Indications Partial epilepsies
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 13 May 2017 Results of a double-blind phase II dose-titration study (core study-NCT01147003), post-hoc analysis of the core study and open-label-extension study (NCT01338805), published in the Epilepsia Journal.
    • 20 Dec 2011 Actual patient number is 93 as reported by ClinicalTrials.gov.
    • 20 Dec 2011 Actual end date Sep 2011 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top